Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Oct 2008Cited by 202 (Europe PMC)

PMID18505369DOI10.1359/jbmr.080506PepBankPUB-18505369

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In women with osteoporosis, teriparatide increased lumbar spine BMD from baseline at each reported visit in all prior-treatment groups.
In plain wordsIn women with osteoporosis, spine bone density increased from baseline during teriparatide treatment in all prior-treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD over follow-up
Study
n = 503
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Lumbar spine BMD increased significantly from baseline at 6, 12, 18, and 24 mo in all three groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536901
02HumanObservational studyEfficacy outcome
In women with osteoporosis, BMD increased significantly between 18 and 24 months of teriparatide treatment.
In plain wordsIn women with osteoporosis, bone density increased significantly between 18 and 24 months of teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLate BMD increase
Study
n = 503
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Increases in BMD between 18 and 24 mo were highly significant.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536909
03HumanObservational studySafety outcome
In women with osteoporosis, nausea occurred in 13.3% during teriparatide treatment.
In plain wordsIn women with osteoporosis, 13.3% reported nausea during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableNausea
Study
n = 503
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Nausea
13.3%
teriparatide
Source sentences
Summary
Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536910
04HumanObservational studySafety outcome
In women with osteoporosis, arthralgia occurred in 11.7% during teriparatide treatment.
In plain wordsIn women with osteoporosis, 11.7% reported joint pain during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableArthralgia
Study
n = 503
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Arthralgia
11.7%
teriparatide
Source sentences
Summary
Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536911
05HumanObservational studySafety outcome
In women with osteoporosis, asymptomatic hypercalcemia occurred in 5.0% during teriparatide treatment.
In plain wordsIn women with osteoporosis, 5.0% developed high blood calcium without symptoms during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableAsymptomatic hypercalcemia
Study
n = 503
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Asymptomatic hypercalcemia
5%
teriparatide
Source sentences
Summary
Asymptomatic hypercalcemia was reported in 5.0% of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536912
06HumanObservational studyEfficacy outcome
In inadequate AR responders, spine BMD increased by 9.8% during teriparatide treatment, less than in treatment-naive women.
In plain wordsIn women with inadequate prior treatment responses, spine bone density increased by 9.8%, less than in treatment-naive women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in inadequate AR responders
Study
n = 285
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Spine BMD gain
9.8%
inadequate AR responders
Spine BMD gain
0.071 g/cm(2)
inadequate AR responders
Source sentences
Summary
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536904
07HumanObservational studyEfficacy outcome
In inadequate AR responders, total hip BMD increased by 2.3% during teriparatide treatment.
In plain wordsIn women with inadequate prior treatment responses, hip bone density increased by 2.3% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD in inadequate AR responders
Study
n = 285
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Hip BMD increase
2.3%
inadequate AR responders
Source sentences
Summary
The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536907
08HumanObservational studyEfficacy outcome
In inadequate AR responders, early hip BMD decreases reversed by 18 months of teriparatide treatment.
In plain wordsIn women with inadequate prior treatment responses, early hip bone density loss reversed by 18 months of teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedEarly hip BMD loss reversal
Study
n = 285
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Early decreases in hip BMD in the inadequate AR responder group were reversed by 18 mo of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536908
09HumanObservational studyEfficacy outcome
In AR-pretreated women with osteoporosis, spine BMD increased by 10.2% during teriparatide treatment, less than in treatment-naive women.
In plain wordsIn previously treated women, spine bone density increased by 10.2% during teriparatide treatment, less than in treatment-naive women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in AR-pretreated women
Study
n = 134
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Spine BMD gain
10.2%
AR-pretreated
Spine BMD gain
0.074 g/cm(2)
AR-pretreated
Source sentences
Summary
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536903
10HumanObservational studyEfficacy outcome
In AR-pretreated women, total hip BMD increased by 2.3% during teriparatide treatment.
In plain wordsIn previously treated women, hip bone density increased by 2.3% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD in AR-pretreated women
Study
n = 134
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Hip BMD increase
2.3%
AR-pretreated
Source sentences
Summary
The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536906
11HumanObservational studyEfficacy outcome
In treatment-naive women with osteoporosis, spine BMD increased by 13.1% during teriparatide treatment.
In plain wordsIn treatment-naive women with osteoporosis, spine bone density increased by 13.1% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in treatment-naive women
Study
n = 84
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Spine BMD gain
13.1%
treatment-naive
Spine BMD gain
0.095 g/cm(2)
treatment-naive
Source sentences
Summary
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536902
12HumanObservational studyEfficacy outcome
In treatment-naive women, total hip BMD increased by 3.8% during teriparatide treatment.
In plain wordsIn treatment-naive women, hip bone density increased by 3.8% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD in treatment-naive women
Study
n = 84
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Hip BMD increase
3.8%
treatment-naive
Source sentences
Summary
The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups.
Summary · context
We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo.
Summary · context
Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractu…
Report a problemFND-1850536905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.